Review of Qilu Pharmaceutical Granisetron Hydrochloride Injection

On April 26, the NMPA official website updated the drug approval document information, and Qilu Pharmaceutical's Granisetron Hydrochloride Injection was the first to pass the consistency evaluation.

Figure 1: Qilu Pharmaceutical's over-rated product information

Source: NMPA official website

Granisetron is a highly selective 5-HT3 receptor antagonist, suitable for the prevention and treatment of nausea and vomiting caused by tumor radiotherapy and chemotherapy.

Table 1: Antiemetics and anti-nausea drugs that have been reviewed/deemed to have been reviewed earlier

Source: Meinenet MED2.

Note: *is the first company to pass the evaluation

According to data from Minei.

Table 2: 2020H1 Qilu's ranking of antiemetics and antinausea brands

Source: Mi Nei.

According to the comprehensive database of the MID Drug Index of Meinenet, Qilu has 7 products related to antiemetics and anti-nausea drugs, 4 of which have entered the TOP20 brand list of terminal antiemetics and anti-nausea drugs in China's public medical institutions in the first half of 2020.

Source: Mi Nei.

The review data statistics are as of April 26, if there are any errors or omissions, please correct me.